Immunofluorescent analysis of Survivin (green) showing staining in the cytoplasm and nucleus of Hela cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a Survivin polyclonal antibody (Product # PA5-16859) in 3% BSA-PBS at a dilution of 1:50 and incubated overnight at 4°C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a fluorescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic peptide derived from the C-terminus of human survivin|
|Storage buffer||PBS, pH 7.6, with 0.2% BSA|
|Contains||15mM sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50|
|Western Blot (WB)||1:100-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA5-16859 targets Survivin in IHC (P), ICC/IF and WB applications and shows reactivity with Human and mouse samples.
The PA5-16859 immunogen is a synthetic peptide derived from the C-terminus of human survivin.
Survivin is a new inhibitor of apoptosis (IAP) protein. It is expressed in the G2/M phase of the cell cycle in a cycle-regulated manner. The overexpression of surviving in cancer may overcome this apoptotic checkpoint and favor aberrant progression of transformed cells through mitosis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice.
PA5-16859 was used in immunohistochemistry - paraffin section to determine if beta-Adrenergic signaling contributes to initiation and progression of breast cancer
|Abdin AA,Soliman NA,Saied EM||Pharmacological reports : PR (66:1114)||2014|
Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.
PA5-16859 was used in immunohistochemistry to investigate the expression of DcR3, survivin and other prognostic factors in B cell non-Hodgkin lymphoma
|Bedewy AM,Elgammal MM,Bedewy MM,El-Maghraby SM||Annals of hematology (92:1359)||2013|
Expression of nuclear factor kappa B and survivin in psoriasis.
PA5-16859 was used in immunohistochemistry to perform a comparative study of NFkB and survivin expression in normal and psoriatic epidermis
|Gunduz K,Temiz P,Gencoglan G,Inanir I,Catalkaya A||ISRN dermatology (2012:null)||2012|
Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL).
PA5-16859 was used in immunohistochemistry to study survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma
|Markovic O,Marisavljevic D,Cemerikic-Martinovic V,Martinovic T,Filipovic B,Stanisavljevic D,Zivkovi¿ R,Hajder J,Stanisavljevic N,Mihaljevic B||Medical oncology (Northwood, London, England) (29:3515)||2012|
Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.
PA5-16859 was used in immunohistochemistry to study the immunohistochemistry of immune escape in ovarian epithelial tumors
|Hasby EA||Pathology oncology research : POR (18:509)||2012|